Entest Group Inc

[1~Eye~Jack!!]

~ ENTB = I Luv da Science!!

,,,but ENTB will be Diluted more soon...

~ RGBP = Making YEARLY Revenue$ NOW!!

Here is the Plain & $imple of this EXCELLENT PLAN = RGBP is working to Cure Many Human Cancers & Diseases. (Don't we ALL want That!! ) = In that process, animals are tested 1st & Cures are found there 1st! = ENTB is working to Cure Cancers & Diseases in animals. (Don't we ALL want That!! ) = ENTB Owns Zander who is Paying RGBP to License RGBP's Intellectual Property. = $mart way to keep Cures that make Money between ENTB & RGBP...
...Now here is a Brilliant part of this Plan = ENTB Pays RGBP with Shares of ENTB that RGBP can Sell for STRAIGHT UP CASH!!! = BOOOM! = NO Need for any Toxic Financiers. = This means ENTB doesn't even pay 1% Note Fee...lol = No more 8% - 12% Toxic Funding,, or Worse... = RGBP just sells the shares Straight up & gets ALL the Funds from the Sale!
...also as a Bonus ,, RGBP can use this "Asset" when/if they were to get a Low Interest Loan...
...Also, their are Royalties paid to RGBP on Top of the $$'s Stated above...

Here is the Math
$100,000 x 15year = $1,500,000 + $100,000 one time fee = $1,600,000+ Royalties!! (***Royalties Minimum $10,000per year!!)

Dr. Koos Degree is finally Paying off!

RGBP 10q
http://ih.advfn.com/p.php?pid=nmona&article=69927680

ENTB 10q
http://ih.advfn.com/p.php?pid=nmona&article=70004820&symbol=ENTB

On June 23, 2015 Regen Biopharma, Inc. ( “Regen”) entered into an agreement (“Agreement”) with Zander whereby Regen granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by Regen (“ License IP”) for non-human veterinary therapeutic use for a term of fifteen years.

Pursuant to the Agreement, Zander shall pay to Regen one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000) as a license initiation fee which must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand US dollars ($100,000) on the first anniversary of the effective date of the Agreement and each subsequent anniversary.

The above mentioned payments may be made, at Zander’s discretion, in cash or newly issued common stock of Zander or in common stock of Entest BioMedical Inc. valued as of the lowest closing price on the principal exchange upon which said common stock trades publicly within the 14 trading days prior to issuance.

Pursuant to the Agreement, Zander shall pay to Regen royalties equal to four percent (4%) of the Net Sales , as such term is defined in the Agreement, of any Licensed Products, as such term is defined in the Agreement, in a Quarter.

Pursuant to the Agreement, Zander will pay Regen ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Zander from sublicensees ( excluding royalties from sublicensees based on Net Sales of any Licensed Products for which Regen receives payment pursuant to the terms and conditions of the Agreement).

Zander is obligated pay to Regen minimum annual royalties of ten thousand US dollars ($10,000) payable per year on each anniversary of the Effective Date of this Agreement, commencing on the second anniversary of June 23, 2015. This minimum annual royalty is only payable to the extent that royalty payments made during the preceding 12-month period do not exceed ten thousand US dollars ($10,000).

The Agreement may be terminated by Regen:

If Zander has not sold any Licensed Product by ten years of the effective date of the Agreement or Zander has not sold any Licensed Product for any twelve (12) month period after Zander’s first commercial sale of a Licensed Product.

The Agreement may be terminated by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United States patent and Trademark Office to Regen with regard to that License IP.

The Agreement may be terminated by Zander with regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to Regen with regard to that License IP is terminated.

The Agreement may be terminated by either party in the event of a material breach by the other party.

On September 28, 2015 the Company issued 8,000,000 of its common shares to Regen in satisfaction of the license initiation fee.